Assessment of cerebral blood flow in diabetic patients with no clinical history of neurological disease.
We assessed cerebral blood flow in 78 diabetic patients (40 Type 1 and 38 Type 2) with no previous history of central nervous system disease using 99Tcm-hexamethylpropylene amine oxime (99Tcm-HMPAO) single photon emission tomography (SPET) and found areas of severe hypoperfusion in 36% of them. All cerebral anatomical regions showed abnormalities related to hypoperfusion, but they were most frequently seen in the fronto-temporal region, followed by the occipital and parietal regions. 99Tcm-HMPAO SPET has been shown to be able to detect subclinical alterations in blood flow in diabetes, a finding that may account for the high prevalence of cerebrovascular disease seen in these patients. This technique could, therefore, play an important role in future preventative strategies.
Servicio de Medicina Nuclear, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
J F
JF
Jimenez-Bonilla
J M
JM
Carril
R
R
Quirce
R
R
Gomez-Barquin
J A
JA
Amado
C
C
Gutierrez-Mendiguchia
D000328:Adult; D000368:Aged; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000209:etiology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000209:etiology; D003929:Diabetic Neuropathies / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon
D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime